Lauren Ashley May MD, Abstract Co-Author: Nothing to Disclose

Prakash Mohan Masand MD, Abstract Co-Author: Nothing to Disclose

Matthew R. Minor MD, Presenter: Nothing to Disclose

Pediatric vascular imaging is particular challenging secondary to the anatomic size and unique physiology of pediatric patients. Current contrast enhanced MR angiography techniques utilizing conventional gadolinium based contrast agents are limited by the need to acquire images relatively quickly during the first pass of contrast material through the vessels of interest. This is to achieve adequate enhancement of vascular structures, for diagnosis, and post-processing. However Gadofosveset trisodium (Ablavar®), a blood pool intravascular contrast agent, has proven to be excellent in this regard. This agent allows first-pass and equilibrium phase imaging of the arterial and venous structures. This exhibit reviews the added benefit of using blood pool contrast in the evaluation of various vascular anomalies, both congenital and acquired.

1) Physiology and Pharmacology of Gadofosveset Trisodium a) Indications and Usage b) Adverse Reactions 2) Suggested MR Imaging Protocol a) First pass and Equlibrium Phase Imaging (Steady state imaging) 3) Applications a) Congenital Heart Disease Imaging, including evaluation of Fontan baffle (post Norwood procedure) b) Congenital Portocaval Shunts c) Paget-Schroetter Syndrome d) Portal hypertension e) Klippel-Trenaunay Syndrome f) Vascular Malformation imaging    

http://abstract.rsna.org/uploads/2014/14015909/14015909_6gxo.pdf

May, L, Masand, P, Minor, M, MR Angiography – Utility of Gadofosveset Trisodium (Ablavar®) in MR Angiography of Pediatric Patients.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015909.html